Document Type
Article
Publication Date
1-1-2024
Abstract
INTRODUCTION AND IMPORTANCE: The feasibility of combined tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer (MIBC) remains to be investigated.
CASE PRESENTATION: The neoadjuvant treatment not only shrunk tumours significantly but also lowered their stages from T4bN1M0, T3N0M0, and T3bN0M0 to pT1, pT0 and pTis, respectively. The treatment suppressed tumour cell proliferation and promoted luminal-to-basal transition.
CLINICAL DISCUSSION: MIBC is an aggressive bladder cancer with poor prognosis. All three patients with MIBC benefited greatly from the neoadjuvant regimen (tislelizumab + gemcitabine + cisplatin). It appears that the effect of the treatment is independent of the levels of programmed death-ligand 1 nor the subtype of urothelial bladder cancer.
CONCLUSION: Combination of tislelizumab with gemcitabine and cisplatin appeared to be a safe and efficacious neoadjuvant therapy for MIBC.
Publication Title
Annals of Medicine and Surgery (London)
Volume
86
Issue
1
First Page
245
Last Page
251
PubMed ID
38222740
Recommended Citation
Wang, Ze; Wang, Yapeng; Wang, Shuo; Ran, Qiang; Peng, Song; Zhang, Yao; Zhang, Jun; Zhang, Dianzheng; Wang, Luofu; Lan, Weihua; Liu, Qiuli; and Jiang, Jun, "Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series." (2024). PCOM Scholarly Papers. 2248.
https://digitalcommons.pcom.edu/scholarly_papers/2248
DOI: https://doi.org/10.1097/MS9.0000000000001533
Comments
This article was published in Annals of Medicine and Surgery (2012), Volume 86, Issue 1, pages 245-251.
The published version is available at https://doi.org/10.1097/ms9.0000000000001533.
Copyright © 2024 The Author(s). CC BY-NC-ND 4.0.